Leap Therapeutics, Inc.
LPTX
$0.41
$0.00-0.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -39.55% | -0.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.12% | -1.63% | |||
| Operating Income | 22.12% | 1.63% | |||
| Income Before Tax | -7.83% | 0.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.83% | -0.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.83% | -0.03% | |||
| EBIT | 22.12% | 1.63% | |||
| EBITDA | 22.12% | 1.64% | |||
| EPS Basic | -7.38% | 1.50% | |||
| Normalized Basic EPS | 21.86% | 50.38% | |||
| EPS Diluted | -7.38% | 1.50% | |||
| Normalized Diluted EPS | 21.86% | 50.38% | |||
| Average Basic Shares Outstanding | 0.43% | 0.04% | |||
| Average Diluted Shares Outstanding | 0.43% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||